Spray-dried pH-sensitive microparticles: effectual methodology to ameliorate the bioavailability of acid labile pravastatin

Abstract

Pravastatin is a promising drug utilized in the treatment of hyperlipidemia, yet, its main clinical limitation is due to gastric liability which fractions its oral bioavailability to less than 18%. The purpose of the current study is to encapsulate pravastatin into Eudragit^®-based spray-dried microparticles aspiring to overcome its acid liability. With the aim to optimize the microparticles, formulation and process parameters were studied through acid resistance challenging test. Physicochemical characterization of the optimized spray-dried pH-sensitive microparticles namely; in-vitro dissolution, surface morphology, compatibility, and solid-state studies were performed. Moreover, in-vivo evaluation of the microparticles and accelerated stability studies were carried out. The results outlined that polymer to drug ratio at 5:1 and pravastatin concentration at 1%w/w in spray-drying feed solution showed 38.55% and 53.97% encapsulation efficiency, respectively. The significance of process parameters specifically; the flow rate and the inlet temperature on microparticles surface integrity were observed, and optimized until encapsulating efficiency reached 72.37%. The scanning electron microscopical examination of the optimized microparticles illustrate uniform smooth surface spheres entrapping the drug in an amorphous state as proved through Differential Scanning Calorimetry (DSC) and Fourier Transfer Infrared (FTIR) studies. The in-vivo evaluation demonstrated a 5-fold enhancement in pravastatin bioavailability compared to the marketed product. The results provided evidence for the significance of spray-dried pH-sensitive microparticles as a promising carrier for pravastatin, decreasing its acid liability, and improving its bioavailability.

Keywords:

• Acid degradation
• bioavailability
• Eudragit
• microparticles
• pravastatin
• spray-drying

View correction statement:

Correction

Acknowledgments

The authors are grateful for the assistance of Dr. Abir Kouzayha, QC manager, Serum Products s.a.r.l. for HPLC, and FTIR studies, Prof. Dr. Roland Habchi, Research platform in Nanoscience and Nanotechnology, Lebanese University, for SEM studies, Dr. Soula Kyriakos, R&D manager, Pharmaline, for DSC studies, Ecole Doctorale, Hadath for XRPD studies. As well, the authors appreciating Algorithm s.a.r.l. and Evonik company for Pravastatin sodium and Eudragit® L30-D55 samples, respectively.

Disclosure statement

No potential conflict of interest was reported by the authors.